Sara E. Martin del Campo

Sara E. Martin del Campo

Auto-generated profile, based on publicly available information

Sara E. Martin del Campo

Providence Swedish Hlth Serv, Dept Surg, Seattle, WA USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSara E. Martin del Campo
Sara E. Martin del Campo
NLNicholas Latchana
Nicholas Latchana
KLKala M. Levine
Kala M. Levine
VGValerie Grignol
Valerie Grignol
EFEne T. Fairchild
Ene T. Fairchild
WCWilliam E Carson
William E Carson
Metastatic melanoma is the most aggressive form of this cancer. It is important to understand factors that increase or decrease metastatic activity in order to more effectively research and implement treatments for melanoma. Increased cell invasion through the extracellular matrix is required for metastasis and is enhanced by matrix metalloproteinases (MMPs). Tissue inhibitor of metalloproteinases 3 (TIMP3) inhibits MMP activity. It was previously shown by our group that miR-21, a potential regulator of TIMP3, is over-expressed in cutaneous melanoma. It was therefore hypothesized that increased levels of miR-21 expression would lead to decreased expression of TIMP3 and thereby enhance the invasiveness of melanoma cells. miR-21 over-expression in the melanoma cell lines WM1552c, WM793b, A375 and MEL 39 was accomplished via transfection with pre-miR-21. Immunoblot analysis of miR-21-overexpressing cell lines revealed reduced expression of TIMP3 as compared to controls. This in turn led to a significant increase in the invasiveness of the radial growth phase cell line WM1552c and the vertical growth phase cell line WM793b (p < 0.05), but not in the metastatic cell lines A375 or MEL 39. The proliferation and migration of miR-21 over-expressing cell lines was not affected. Reduced expression of TIMP3 was achieved by siRNA knockdown and significantly enhanced invasion of melanoma cell lines, mimicking the effects of miR-21 over-expression. Treatment of tumor cells with a linked nucleic acid antagomir to miR-21 inhibited tumor growth and increased tumor expression of TIMP3 in vivo in 01B74 Athymic NCr-nu/nu mice. Intra-tumoral injections of anti-miR-21 produced similar effects. This data shows that increased expression of miR-21 enhanced the invasive potential of melanoma cell lines through TIMP3 inhibition. Therefore, inhibition of miR-21 in melanoma may reduce melanoma invasiveness.

1 September 2015 in American Journal of Roentgenology
Verified
Journal Article
Closed access
ASAndrew D. Smith
Andrew D. Smith
MGMark R. Gray
Mark R. Gray
SCSara Martin del Campo
Sara Martin del Campo
DSDarya Shlapak
Darya Shlapak
BGBalaji Ganeshan
Balaji Ganeshan
WCWilliam E Carson
William E Carson
OBJECTIVE. The purpose of this study was to use CT texture analysis to predict overall survival (OS) in patients with metastatic melanoma and stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (RECIST) on initial posttherapy CT images. MATERIALS AND METHODS. This retrospective study included 42 patients with metastatic melanoma who received bevacizumab therapy in the context of a randomized prospective phase II clinical trial. Target lesions on the baseline and initial posttherapy contrast-enhanced CT examinations were evaluated by CT texture analysis using TexRAD software before and after image filtering in patients with RECIST SD on initial posttherapy images. Cox proportional hazards models were used to assess the associations of CT texture analysis measurements and of other patient factors with OS. The AUC was used to evaluate predictive accuracy. RESULTS. In multivariate analysis (in 23 patients with RECIST SD; median OS, 1.51 years), absolute change in mean positive pi...

1 December 2015 in Surgical Oncology
Verified
Journal Article
Closed access
VGValerie Grignol
Valerie Grignol
ASAndrew D. Smith
Andrew D. Smith
DSDarya Shlapak
Darya Shlapak
XZXu Zhang
Xu Zhang
SCSara Martin Del Campo
Sara Martin Del Campo
WCWilliam E Carson
William E Carson

1 April 2018 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
SCSara E. Martin del Campo
Sara E. Martin del Campo
DMDean J. Mikami
Dean J. Mikami
BNBradley J. Needleman
Bradley J. Needleman
SNSabrena F. Noria
Sabrena F. Noria

28 July 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NLNicholas Latchana
Nicholas Latchana
SCSara E. Martin del Campo
Sara E. Martin del Campo
VGValerie Grignol
Valerie Grignol
JCJennifer R. Clark
Jennifer R. Clark
SAScott P. Albert
Scott P. Albert
WCWilliam E Carson
William E Carson

19 June 2024 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
HLHenry Lin
Henry Lin
JBJohn W. Baker
John W. Baker
KMKatherine Meister
Katherine Meister
KLKathleen L. Lak
Kathleen L. Lak
SCSara E. Martin Del Campo
Sara E. Martin Del Campo
APAnthony Petrick
Anthony Petrick
Background: Clinical care pathways help guide and provide structure to clinicians and providers to improve healthcare delivery and quality. The Quality Improvement and Patient Safety Committee (QIPS) of the American Society for Metabolic and Bariatric Surgery (ASMBS) has previously published care pathways for the performance of laparoscopic sleeve gastrectomy (LSG) and pre-operative care of patients undergoing Roux-en-Y gastric bypass (RYGB). Objective: This current RYGB care pathway was created to address intraoperative care, defined as care occurring on the day of surgery from the preoperative holding area, through the operating room, and into the postanesthesia care unit (PACU). Methods: PubMed queries were performed from January 2001 to December 2019 and reviewed according to Level of Evidence regarding specific key questions developed by the committee. Results: Evidence-based recommendations are made for care of patients undergoing RYGB including the pre-operative holding area, intra-operative management and performance of RYGB, and concurrent procedures. Conclusions: This document may provide guidance based on recent evidence to bariatric surgeons and providers for the intra-operative care for minimally invasive RYGB.